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characteristics (CD34, CD3, CD19, NK, DC1and DC2 cell dose).
Survival curve analysis by a log rank test revealed that the low DC2
group had a signiﬁcant risk of developing acute and chronic
GVHD (P0.000 for both). These results suggest that the DC2
count in the peripheral blood on day-28 is a strong predictor for
development of GVHD in recipients of PBSC in a matched related
allogeneic SCT.
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A CDNA-BASED ASSAY FOR DONOR-CHIMERISM ANALYSIS OF EPIDER-
MAL LANGERHANS CELLS
Bakhtiar, S.1, Bender, K.2, Schmitt, T.1, Moench, C.3, Konur, A.1,
Huber, C.1, Herr, W.1, Meyer, R.G.1 1Johannes Gutenberg University,
Mainz, Germany; 2Johannes Gutenberg University, Department of
Legal Medicine, Mainz, Germany; 3Johannes Gutenberg University,
Department of Transplantation Surgery, Mainz, Germany.
Early acute GVHD of the skin frequently occurs in patients after
allogeneic hematopoietic stem cell transplantation. T cell depletion
sufﬁciently reduces incidence and severity, but does not completely
prevent skin GVHD which then leads to a prolonged need for im-
munosuppressive medication. The activation of donor T cells by
residing host antigen presenting cells such as epidermal Langerhans
cells (LCs) plays a central role in the initiation of acute GVHD. The
absence of donor T cells after depletion delays the switch of LCs from
host to donor origin in mice. We and others have provided evidence
for a delayed switch in LC chimerism after T cell depleted reduced
intensity stem cell transplantation in humans. However, most assays
used so far either depend on the detection of the Y-chromosome in
skin sections of sex-mismatched transplants. In an attempt to set up a
sensitive assay of general applicability, we combined the detection of
donor chimerism and tissue speciﬁc markers in a single multiplex
PCR. We established RT-PCRs for 10 different constitutively ex-
pressed genes containing single nucleotide polymorphisms (SNPs)
inside their coding regions. These PCRs were combined in a single
multiplex PCR and the SNPs were analyzed by the primer extension
method (minisequencing) and separated by capillary electrophoresis.
We tested this approach on PBMCs of 10 patients and their HLA-
matched sibling donors. The assay distinguished all pairs in 1 to 6 out
of 10 systems. In a subsequent step, the 10plex PCR was combined
with the tissue speciﬁc markers langerin for LCs and cytokeratin 10 to
distinguish LCs from keratinocytes. The expression of langerin and
cytokeratin 10 was detected using gene-speciﬁc probes in the same
minisequencing reaction used for the detection of SNPs. The result-
ing 12plex assay distinguished sibling donors from the patients with
the same speciﬁcity and, in the same reaction, detected Langerin as
well as cytokeratin 10 in puriﬁed LCs and keratinocytes, respectively.
In summary, we established a sensitive assay allowing simultaneous
detection of donor chimerism together with the tissue speciﬁcity of
isolated LCs that is independent of sex-mismatched donors. The
addition of further tissue speciﬁc markers might allow performing
chimerism studies on other tissue resident antigen presenting cells.
The use of a cDNA-based assay might also allow combining chimer-
ism analysis with activation- and maturation speciﬁc markers in a
single assay.
314
SELECTIVE DEPLETION OF ALLOREACTING T CELLS BY TH9402-BASED
PHOTODEPLETION AS A TRANSLATIONAL STRATEGY FOR GVHD CON-
TROL IN HLA-MISMATCHED AND MATCHED DONOR-RECIPIENT PAIRS
Mielke, S.1, Nunes, R.1, Rezvani, K.1, Fellowes, V.S.2, Fan, Y.2,
Scotto, C.3, Solomon, S.P.1, Read, E.J.2, Barrett, A.J.1 1Stem Cell
Allotransplantation Section, Hematology Branch, NHLBI, NIH, Be-
thesda, MD; 2Cell Processing Section, Department of Transfusion Med-
icine, NIH, Bethesda, MD; 3Celmed Biosciences Inc., Saint-Laurent,
QC, Canada.
Selective depletion (SD) is a strategy to eliminate host-reactive
donor lymphocytes from blood stem cell allografts to prevent GVHD
and maintain GVL-effects. We investigated a photodepletion (PD)
process, whereby allo-activated donor cells are labeled with a photo-
sensitizing rhodamine-based dye, 4,5-dibromorhodamide 123
(TH9402), and exposed to visible light, which preferentially elimi-
nates allo-activated dye-retaining cells. Stimulator cells were prepared
from recipient-derived leukapheresis mononuclear cells (MNCs) and
cultured using anti-CD3 and 100 IU IL-2/ml. Responder cells (leu-
kapheresis MNCs) from 3 random HLA-mismatched volunteers and
3 HLA-matched sibling donors were cocultured 1:1 with irradiated
stimulators for 3 days. Cultured cells were incubated with 7.5 	M
TH9402, followed by dye-extrusion and exposure to 5 Joule light
energy in the PD light source (Celmed Bioscience Inc., Canada) at
510
6
cells/ml in FEP plastic bags. Depletion efﬁcacy was studied by
mixed lymphocyte reactions (MLR) in mismatched pairs and by help-
er-T-lymphocyte precursor (HTLp) frequency assay in matched
pairs. All six clinical-scale experiments provided sufﬁcient reduction of
allo-reactivity and retention of third party responses as measured
against a pool of 5 donors. In mismatched pairs mean reduction of
allo-reactivity was 703-fold ( 141) when compared to unmanipu-
lated donors. Third-party responses were maintained, with a mean
reduction of only 1.3  0.15-fold. In matched pairs alloreactivity was
reduced below the “GVHD-threshold” of 1/100.000 whilst third
party responses remained above 1/10.000 precursors. This establishes
a clinical scale PD process capable of highly efﬁcient removal of
alloreactive lymphocytes from mismatched and matched MLRs while
maintaining desirable third party responses. As PD targets activation-
based changes in MDR-1 that result in an altered dye efﬂux, the
mechanism of action is distinct from surface-marker-based allodeple-
tion (e.g. CD69, CD25). Thus, PD may overcome instability of
activation-based surface marker expression resulting in more consis-
tent and effective depletion. This approach will now be tested in a
clinical SD trial.
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PHARMACOKINETICS (PK) OF MYCOPHENOLATE MOFETIL (MMF) IN
PEDIATRIC ALLOGENEIC STEM CELL TRANSPLANT (ALLOSCT) RECIP-
IENTS
Militano, O.1, Hedgpeth, D.2, Shaw, L.M.5, Figurski, M.5,
Satwani, P.2, Ayello, J.2, Roman, E.2, Bradley, B.2, George, D.2,
Garvn, J.2, Bhatia, M.2, Wolownick, K.2, Foley, S.2, Hawkes, R.2,
Cairo, M.S.2,3,4 1Department of Pathology, NewYork-Presbyterian, Co-
lumbia University; 2Pediatrics; 3Medicine; 4and Pathology; 5Pathology
and Laboratory Medicine, University of Pennsylvania.
MMF PK in children may impact on the incidence of moderate/
severe acute GVHD following AlloSCT (Osunkwo/Cairo et al,
BBMT 2004). The objective of this study is to evaluate effects of age
on the PK of MMF in pediatric AlloSCT recipients. From 1/04 –
8/06 we enrolled 31 pediatric AlloSCT with 27 being evaluable: mean
age 8.5 yrs; wt 34.3 kg; M:F12:15; NBL PR (n3), SCD (n3),
AML (CR1 [n4], CR2 [n1], CR3 [n1], relapsed/induction fail-
ure [n3]), SAA (n5), CML CP (n1), ALL (CR1 [n1], CR2
[n2], CR3 [n1]), HD CR2 (n1), ALCL refractory (n1); donor
sources: MFD (6/6 PBSC [n7], 6/6 BM [n3], 5/6 PBSC [n3]),
6/6 related CB (n1), UCB (6/6 [n2], 5/6 [n3], 4/6 [n7]), and
8/10MUDPBSC (n1). Cohort 1 [ 6 yrs] (n8); 2 [6-12 yrs of age]
(n9); 3 [12–16 yrs] (n10). GVHD prophylaxis included tacrolimus
(onDay –1 or 1st day of conditioning to maintain concentrations 5-20
ng/mL) and MMF (900 mg/m2 IV Q6H starting on Day 1, then
converted to PO [same dose] after Day14). Serum samples forMPA
were drawn on Day 1, 7, and 14 at hour 0, 0.5, 1, 2, 3, 4, and 6
post-dose. MPA plasma concentrations were determined by reverse-
phase HPLC.MMF dose was adjusted to maintainMPA trough 1-3.5
mg/L. The mean CD34 cell dose/kg 27.5105, TNC dose/kg
50.3107. Time to neutrophil (ANC  500/mm3 x 2 d) and platelet
engraftment (untransfused count  20K x 7 d) was 22 d and 36 d,
respectively. Mean f/u was 448 d. Mean MPA PK on Day 14:
Cmax17.6 mg/L, Tmax1.82 h, total MPA trough0.85 mg/L,
AUC0-639.4 mg  hr/L, T1/21.3 h, Vd1.5 L/kg, and CL1.2
L/kg/h at a mean MMF dose of 1056 mg/m2 IV Q6H. Age cohorts
are shown in Table 1. Incidence of GI adverse events attributable to
MMF was 59% (nausea/vomiting [n13], diarrhea [n8], abdominal
pain [n3], pneumatosis intestinalis [n1], gastritis/colitis [n2]).
Kaplan-Meier probability of grade II-IV aGVHD following related
[n14] and unrelated [n13] donors was 60.8% (15/27 evaluable pts),
cGVHD was 25.2% (5/22 evaluable pts) and 1 year OS was 64.4%
(CI: 45.6-83.1%). In comparison to MMF PK in adult AlloSCT pts
Poster Session II114
receiving cyclosporine/MMF (Nash et al, BBMT 2005), children have
signiﬁcantly higher MMF clearance rates (1.2 vs 0.54 L/kg/h). MMF
doses  3-fold higher than those used in pediatric SOT recipients
were required to achieve AUC0-630-60 mg  h/L. Short T1/2 and
rapid clearance of MMF in pediatric AlloSCT pts may be related to a
lack of enterohepatic recycling and enhanced UDP-glucuronosyl-
transferase activity.
Table 1. Age-related IV MMF PK on Day 14.
Age
Group
Cmax
(mg/L)
Tmax
(h)
Total
MPA
trough
(mg/L)
Mean
AUC0-6
(mg  h/L)
T1/2
(h)
Vss
(L/kg)
CL
(L/kg/h)
< 6
y.o.
(n8) 13.8 1.9 1.2 37.1 1.7 2.1 1.4
6-12
y.o.
(n8) 14.8 2.0 0.4 35.8 0.9 1.4 1.3
12-16
y.o.
(n7) 25.2 1.6 1.1 45.8 1.3 1.2 0.8
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CHARACTERISTICS OF CHRONIC GRAFT-VERSUS-HOST DISEASE IN
BRAZILIAN RECIPIENTS OF ALLOGENEIC STEM CELL TRANSPLANTS: A
FIVE-YEAR RETROSPECTIVE ANALYSIS
Bouzas, L.F.S.1, Moreira, M.C.P.1, Tavares, R.d.C.B.1, Lerner, D.1,
Azevedo, A.M.1, Mattos, M.1, Horn, P.1, Collares, M.1, Mellin, S.1
1Instituto Nacional do Cancer, Rio de Janeiro, Brazil.
Chronic graft-versus-host disease (cGVHD) is the leading cause
of non-relapse morbidity and mortality in the post-transplantation
period. Incidence rates and clinical characteristics have been
changing considerably in recent years, following increases in the
use of new sources of stem cells and donor/recipient age and the
introduction of new modalities of conditioning regimens. Inci-
dence rates reported in the literature have ranged from 20 to 70%,
being lower in the pediatric population and in recipients of cord
blood grafts. Use of donor lymphocyte infusions as a strategy to
control minimal residual disease or treat relapse is also a risk factor
for cGVHD. Among 95 patients analyzed, 29 (30.5%) were fe-
males. Median age was 35 years (18-64). Eighty seven patients had
hematologic malignancies (91.5%). The conditioning regimen was
myeloablative in 79 (83%). Bone marrow was used in 74 (78%) and
peripheral blood in 21 (22%). Prophylaxis of GVHD was done
with cyclosporine and methotrexate in 88 (92.5%). Sixty six
(69.5%) patients had acute GVHD before cGVHD. The median
time for the ﬁrst manifestation of cGVHD was 132 days (33-1499).
The installation of cGVHD was progressive in 37 (49%). Extensive
disease was present in 42 (56%). Eosinophilia (500/ul) was found
in 12 (16.5%). Lymphopenia (500/ul) was present in 19 (25%).
Thrombocytopenia ( 100,000/ul) was seen in 32 (41.5%). The
ﬁndings in our series are in accordance with the clinical proﬁle
usually reported in the literature. Because of its high morbidity and
mortality, the need for early detection of cGVHD can not be
overstated. Systematic, prospective evaluation of patients at risk for
this complication can contribute to better understanding of the
disease, and possibly, better control of the complications and im-
pact of advanced cGVHD in quality of life and survival expectancy.
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PRE-TRANSPLANT BIOMARKERS PREDICT GVHD AND TREATMENT-
RELATED MORTALITY IN PATIENTS TREATED WITH EXTRACORPO-
REAL PHOTOPHERESIS PRIOR TO ALLOGENEIC BONE MARROW
TRANSPLANTATION
O’Brien, P.J.1, Bolwell, B.2, Abhyankar, S.3, Shaughnessy, P.4,
Williamson, P.1, Campbell, K.A.1 1Therakos Inc., Exton, PA; 2The
Cleveland Clinic Foundation Bone Marrow Transplant, Cleveland, OH;
3Kansas City Cancer Center, Kansas City, MO; 4Texas Transplant
Institute, San Antonio, TX; 5University of Chicago, Chicago, IL.
Accurate prediction of the onset and severity of GvHD and
treatment-related mortality (TRM) can improve outcomes
through optimized donor selection and GvHD prophylaxis. Cur-
rent assessments are typically made after bone marrow transplan-
tation (BMT), and often require inherently unreliable qualitative
measures. The persistence of host antigen presenting cells, partic-
ularly dendritic cells (DC) has been implicated in the onset of
GvHD, and a recent data suggests that extracorporeal photophere-
sis (ECP) can prevent GvHD after allogeneic BMT. We examined
blood from 32 ECP-treated patients to identify cell surface mark-
ers that might predict GvHD and TRM. Samples were drawn
immediately prior to ECP (at baseline) and immediately after ECP,
but prior to myeloablative conditioning, then assayed by ﬂow
cytometry. Cytometry data were grouped and modeled to assess
their predictive accuracy alone or in combination with clinical
laboratory values. Logistic regression showed that speciﬁc DC
subsets present prior to myeloablation were the best predictors of
outcomes. The likelihood of grade II-IV GvHD (aGvHD) in-
creases when baseline lin- HLA-DR CD11c myeloid cells make
up a smaller proportion of circulating mononuclear cells with a
predictive accuracy, reﬂected in the area under the receiver-oper-
ator curve (ROC) of 0.83. The best predictive model for TRM was
a lower absolute abundance of circulating lin- HLA-DR CD123
plasmacytoid DC at baseline (ROC0.86). No additional predic-
tive power arose with respect to aGvHD or TRM after including
laboratory values. Models that combined certain clinical laboratory
results and demographic factors also predicted these clinical out-
comes, and offer a possible alternative to complex cytometric
assays. The best such model included baseline measurements of
BUN/Creatinine ratio, serum albumin, and the match/relatedness
of the graft donor and recipient (ROC0.82, n59) for TRM,
while baseline neutrophil counts were most predictive of aGvHD
(ROC0.69, n60).
In summary, we have identiﬁed biomarkers that, at least in
patients receiving ECP, are present before conditioning and can
predict outcomes. Although this study does not address the impact
of ECP on antigen presenting cells directly, the DC proﬁles de-
scribed here highlight the potential role of ECP in modulating
DC, and thereby decreasing the risks associated with BMT. These
results encourage larger studies with non-ECP control populations
to directly address this issue.
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EXTRACORPOREAL PHOTOPHERESIS (ECP) FOR THE TREATMENT OF
STEROID-REFRACTORY OR -INTOLERANT CHRONIC GRAFT-VERSUS-
HOST DISEASE (CGVHD) FOLLOWING ALLOGENEIC HEMATOPOIETIC
STEM CELL TRANSPLANT (HSCT)
Pawarode, A.1,2, Hahn, T.1, Battiwalla, M.1, McCarthy, P.L.1 1BMT
Section, Department of Medicine, Roswell Park Cancer Institute, Buf-
falo, NY; 2Division of Hematology, Department of Medicine, University
at Buffalo School of Medicine and Biomedical Sciences, Buffalo, NY.
We report our long-term results using extracorporeal photo-
pheresis (ECP) for the treatment of chronic graft-versus-host dis-
ease (cGvHD). Between 2002 and 2005, 21 patients with steroid-
refractory or -intolerant cGvHD received ECP for a median
duration of 10.8 (range 1.3-58.8) months (Table). HSCT types
were 14 HLA-matched related donor (MRD), 6 HLA-matched
unrelated donor (MUD) and 1 HLA-mismatched unrelated cord
blood donor. Standard GvHD prophylaxis included a calcineurin
inhibitor with methotrexate (18), or methylprednisolone (2) or
both (1). Two (9.5%), 11 (52.4%) and 8 (38.1%) cases had mild,
moderate and severe cGvHD by CIBMTR criteria. Among the 19
patients with adequate follow-up (6 months post ECP initiation),
the sustained overall and complete response (OR and CR) rates
were 84.2 % (16/19) and 42.1% (8/19) with the maximum response
occurring at the median time of 1.8 (0.6-3.5) months from ECP
initiation. OR and CR rates by CIBMTR severity grading were
50% and 50% in the mild group, 45.4% and 36.4% in moderate
group, and 62.5% and 37.5% in severe group. Steroid-sparing
(steroid discontinuation or requiring adrenal doses only) was
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